Zynex, Inc. is a medical technology company focused on the development, manufacturing, and marketing of electrotherapy devices. These devices are primarily designed to alleviate both chronic and acute pain, and to facilitate muscle activation and rehabilitation. The company's core product offerings include several electrical stimulation devices: NexWave: A versatile, dual-channel device combining interferential current, Transcutaneous Electrical Nerve Stimulation (TENS), and Neuromuscular Electrical Stimulation (NMES) modalities. It is actively promoted to healthcare professionals by the company's field sales team. NeuroMove: An innovative device integrating electromyography with electrical stimulation technology. InWave: An electrical stimulation product specifically engineered for the treatment of female urinary incontinence. E-Wave and M-Wave: Both are specialized NMES devices. Beyond its proprietary devices, Zynex also supplies private-label accessories essential for electrotherapy, such as electrodes for current delivery to the body and batteries to power its products. Furthermore, the company distributes a range of complementary rehabilitation equipment from other manufacturers, including Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, various braces for knee and wrist rehabilitation, and Dynacomp for cold compression therapy. Zynex is also actively engaged in the development of advanced patient monitoring systems. Its pipeline features the Zynex Fluid Monitoring Systems (CM-1500 and the wireless CM-1600), which are non-invasive devices designed to track relative fluid volume changes in adult patients. Other forthcoming monitoring technologies include the NiCO CO-Oximeter, a laser photoplethysmographic device, and the HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company's diverse product portfolio serves critical medical applications, including pain management and control, rehabilitation for stroke and spinal cord injuries, and sophisticated fluid and pulse oximetry monitoring. Zynex primarily sells its products directly to customers through its dedicated sales force, operating predominantly within the United States. Established in 1996, Zynex, Inc. maintains its corporate headquarters in Englewood, Colorado. However, on December 15, 2025, Zynex, Inc. and its affiliated entities filed for Chapter 11 bankruptcy protection, seeking reorganization in the U.S. Bankruptcy Court for the Southern District of Texas.
The current price of ZYXIQ is $0.06 USD — it has increased by +15.38% in the past 24 hours. Watch Zynex stock price performance more closely on the chart.
What is Zynex stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTCQB exchange Zynex stocks are traded under the ticker ZYXIQ.
What is Zynex market cap?▼
Today Zynex has the market capitalization of 1.82M
What is Zynex revenue for the last year?▼
Zynex revenue for the last year amounts to 384.71M USD.
What is Zynex net income for the last year?▼
ZYXIQ net income for the last year is 5.99M USD.
Does Zynex pay dividends?▼
Yes, ZYXIQ dividends are paid en. The last dividend per share was 0.1 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Zynex have?▼
As of August 22, 2026, the company has 1,000 employees.
In which sector is Zynex located?▼
Zynex operates in the Health & Wellness sector.
When did Zynex complete a stock split?▼
The last stock split for Zynex was on January 05, 2022 with a ratio of 1.1:1.
Where is Zynex headquartered?▼
Zynex is headquartered in Englewood, United States.